key: cord-0333088-08ekcll7 authors: Karanika, Styliani; Gordy, James T.; Neupane, Pranita; Karantanos, Theodoros; Castillo, Jennie Ruelas; Quijada, Darla; Comstock, Kaitlyn; Sandhu, Avinaash Kaur; Hui, Yinan; Ayeh, Samuel K.; Tasneen, Rokeya; Krug, Stefanie; Danchik, Carina; Wang, Tianyin; Schill, Courtney; Markham, Rirchard B.; Karakousis, Petros C. title: An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis date: 2022-04-19 journal: bioRxiv DOI: 10.1101/2022.04.19.488816 sha: b1bf39aa986c321f8a7bde9dee369f2ba0e8107b doc_id: 333088 cord_uid: 08ekcll7 Lengthy tuberculosis (TB) treatment is required to address the ability of a subpopulation of persistent Mycobacterium tuberculosis (Mtb) to remain in a non-replicating, antibiotic-tolerant state characterized by metabolic remodeling, including induction of the RelMtb-mediated stringent response. We developed a novel therapeutic DNA vaccine construct involving fusion of the relMtb gene with the immature dendritic cell-targeting gene encoding chemokine MIP-3α/CCL20. To augment mucosal immune responses, intranasal delivery was also evaluated. We found that the intramuscular MIP-3α/relMtb (fusion) vaccine potentiates isoniazid activity more than a similar DNA vaccine expressing relMtb alone in a chronic TB mouse model (absolute reduction of Mtb burden: 0.63 log10 colony-forming units, P=0.0001), inducing pronounced Mtb-protective immune signatures. The intranasal fusion vaccine, an approach combining relMtb fusion to MIP-3α and intranasal delivery, demonstrated the greatest therapeutic effect compared to each approach alone, as evidenced by robust Th1 and Th17 responses systemically and locally and the greatest mycobactericidal activity when combined with isoniazid (absolute reduction of Mtb burden: 1.13 log10, P<0.0001, when compared to the intramuscular vaccine targeting relMtb alone). This DNA vaccination strategy may be a promising adjunctive approach combined with standard therapy to shorten curative TB treatment, and also serve as proof-of-concept for treating other chronic infections. Tuberculosis (TB) is a major cause of morbidity, and the second leading infectious killer after COVID-19 worldwide (1). The current six-month regimen, consisting of isoniazid (INH), rifampin, pyrazinamide and ethambutol, has high efficacy against drug-sensitive TB, but its length and complexity contributes to treatment interruptions that jeopardize cure and promote drug resistance (2, 3) . Although novel, treatment-shortening antibiotic regimens have shown promising results in international clinical trials (4, 5) , the resources required for direct observation of daily treatment and the associated costs may still pose barriers to their implementation in TB-endemic countries. Recent work has focused on adjunctive, host-directed strategies to simplify and shorten the course of TB therapy (6) . The need for prolonged TB treatment is believed to reflect the unique ability of a subpopulation of Mycobacterium tuberculosis (Mtb) bacilli within the infected host to remain in a nonreplicating, persistent state (7) characterized by tolerance to first-line anti-TB drugs, like INH, which more effectively targets actively dividing bacilli (8) (9) (10) (11) . One of the key bacterial pathways implicated in antibiotic tolerance is the stringent response, which is regulated by the (p)ppGpp synthase/hydrolase, RelMtb (12, 13) . RelMtb deficiency results in defective Mtb survival under nutrient starvation (14) , in mouse lungs (15) and mouse hypoxic granulomas (16) , reduced virulence in guinea pigs (17) and C3HeB/FeJ mice (18) , and increased susceptibility of Mtb to INH in mouse lungs (18) , rendering RelMtb an attractive target for novel anitubercular therapies, including for drug-resistant TB (13) . We previously showed that intramuscular (IM) delivery of a DNA vaccine expressing relMtb enhanced the mycobactericidal activity of INH in a murine TB model (3, 19) . In independent studies, our group has shown the enhanced efficacy of vaccines when the antigen of interest was fused to the gene encoding the chemokine Macrophage Inflammatory Protein-3 alpha/C-C Motif Chemokine Ligand 20 (MIP-3α/CCL20) (20) (21) (22) . This chemokine targets the antigen of interest to immature dendritic cells (DCs) and, compared to vaccines without the MIP-3α component, has shown enhanced T-cell responses in both melanoma and malaria model systems (20) (21) (22) . Since T-cell immunity is required to control Mtb infection (6) , we hypothesized that fusion of relMtb to the chemokine gene MIP-3α (MIP-3α/relMtb or "fusion vaccine") would enhance the immunogenicity of the relMtb vaccine and further potentiate the mycobactericidal activity of INH in vivo. Protection against pulmonary TB is associated with the ability of anti-Mtb T-cells to exit the pulmonary vasculature and enter into the lung parenchyma and airways (23) . Intranasal (IN) vaccination has been shown to promote recruitment of antigenexperienced T cells to these restricted lung compartments in contrast to parenteral immunization (23) . Thus, we also hypothesized that IN administration of the vaccine expressing relMtb alone or the fusion vaccine would further augment T-cell responses within the lung, the primary site of Mtb infection. Here, we present our bacteriological and immunological findings on IM vs. IN immunization with a DNA vaccine expressing relMtb alone or the fusion construct in a murine model of chronic TB. Our results indicate that relMtb fusion to MIP-3α and IN vaccination ("optimized vaccination strategy") yielded the highest additive therapeutic effect compared to each single approach alone. (3, 19) , served as our baseline comparator in this study ("comparator" vaccine). For IN delivery, only the HD vaccine was tested to compensate for the anticipated reduced plasmid uptake without electroporation, which cannot be used with this vaccination route. One negative control group received no treatment, while another group received INH only. All vaccinated groups received INH in addition to the tested vaccines. Since DNA vaccination alone did not exhibit significant mycobactericidal activity in prior work (19) , this group was not included in the present study. For simplicity, we have included only the SD IM vaccine groups and not the HD IM groups, since both IM groups yielded similar microbiological outcomes. Relative to the comparator vaccine, the IM fusion vaccine elicited substantially higher numbers of RelMtb-specific, IFN-γ-producing CD4+ and CD8+ T lymphocytes in the spleens (P<0.0001 and P<0.0001; Figure 2A and B), but not in the lungs of infected mice ( Figure 2C and 2D). Relative to the comparator vaccine, the IM-delivered fusion vaccine was also associated with significantly increased numbers of RelMtb-specific, TNF-α-producing CD4+ T cells (P=0.0076, Figure 2E In an independent immunogenicity study using uninfected animals ( Figure 3A Figure 2C and 2D, respectively) compared to the IM-delivered fusion vaccine. The optimized vaccination strategy also induced higher numbers of RelMtb-specific, TNF-α-producing CD4+ and CD8+ Tcells in the spleens compared to the IM-delivered fusion vaccine (P<0.0001 and P<0.0001, Figure 2E and 2F, respectively). RelMtb-specific, IL-2-producing CD4+ and CD8+ T cells in the spleens of infected mice were similarly high irrespective of the route of delivery of the fusion vaccine ( Figure 2G and 2H). Infected mice receiving the optimized vaccination strategy showed a significantly higher percentage of RelMtbspecific, IL-17α-producing CD4+ T cells in the lungs and spleens compared to those receiving the fusion vaccine by the IM route (P<0.0001 and P<0.0001, Figure 2I and 2J). Relative to IN vaccination with the relMtb vaccine, the optimized vaccination strategy elicited greater numbers of Rel Mtb -specific, IFN-γ-producing CD4+ and CD8+ T cells in the spleens (P<0.0001 and P<0.0001, Figure 2A and 2B, respectively) and in the lungs (P=0.034 and P=0.0064, Figure 2C and 2D, respectively) of infected mice. The optimized vaccination strategy also resulted in higher numbers of RelMtb-specific, TNF-αproducing CD4+ and CD8+ T cels in the spleens compared to mice receiving the relMtb vaccine (P=0.0003 and P<0.0001, Figure 2E and 2F, respectively). RelMtb-specific IL-2producing CD4+ and CD8+ T lymphocytes in the spleens were similarly high in the optimized vaccination group and the IN relMtb group ( Figure 2G and 2H). Mice receiving the optimized vaccination strategy showed a significantly higher percentage of RelMtbspecific, IL-17α-producing CD4+ T cells in the spleens compared to mice receiving the relMtb vaccine by the IN route (P<0.0001, Figure 2J ), but no difference between the two groups was noted in the lungs ( Figure 2I ). Of note, no IL-17α response was observed at these sites following IM immunization. In an independent immunogenicity study using uninfected animals ( Figure 3A ), we found that, compared to fusion vaccine given IM, the optimized vaccination strategy elicited more robust RelMtb-specific, IL-17α CD4+ T-cell responses in the draining LNs (P=0.0033, Figures 3B) and higher RelMtb-specific, IL-17α CD4+ T-cell responses in PBMCs (P=0.0079, Figure 3C ). The optimized vaccination strategy also induced a higher percentage of RelMtb-specific, TNF-α-producing CD4+ T cells at 42 days compared to the fusion vaccine given IM (P=0.03, Figure 3D ). IN vaccination with the relMtb vaccine elicited a higher percentage of RelMtb-specific, IL-17α-producing CD4+ T cells relative to the comparator in the draining LNs (P=00003, Figure 3B ) and PBMCs (P=0.0007, Figure 3C ). Finally, by day 42 after primary vaccination, IN delivery of the relMtb vaccine induced higher proportions of RelMtb-specific, TNF-α-producing CD4+ T cells in PBMCs relative to the comparator (P=0.036, Figure 3D ). The individual statistical comparisons of immunological outcomes in uninfected mice resulting from different vaccination protocols are available in Supplementary Table 3 . Collectively, the optimized vaccination strategy, which was shown to have the most favorable microbiological outcomes over any other tested vaccination approache ( Figure 1C ), was also found, in parallel, to significantly increase the production of multiple cytokines associated with Mtb control, both systemically and at the site of infection. More specifically, compared to any other approach, the optimized vaccination strategy induced the highest numbers of Rel Mtb -specific CD4+ and CD8+ T cells producing IL17-α,TNF-α, IFN-γ, and IL-in the spleens and lungs of Mtb-infected animals ( Figure 4A , 3B, 3C, Supplementary Table 2) , as well as the highest normalized production of each individual cytokine ( Figures 4D, 4E, 4F, 4G, 4H, 4I ). The development of novel immunotherapeutic regimens that synergize with antibiotics to accelerate curative TB treatment is an attractive strategy for improving medical adherence and treatment completion rates, and for reducing costs (24) (3), may represent promising targets for therapeutic vaccines in an effort to "re-educate" the immune system to tailor host anti-TB responses. In the current study, we focused on improving RelMtb-specific T-cell responses by enhancing the engagement of immature DCs. Immature DCs are critical for the activation of adaptive immunity, and, eventually, mature DCs trigger antigen-specific naïve T cells (32) . Of note, only a small minority of DCs are attracted to sites of immunization (32) , and, in the case of HIV and TB infections, a proportion of the attracted DCs may be dysfunctional (33) . Fusion of the antigen of interest to the chemokine MIP-3α (or CCL20) targets the antigen to immature DCs (24) . It has been shown that following naked DNA vaccination, epidermal cells secrete the antigen of interest-chemokine MIP-3α fusion construct (20, 34) . The secreted fusion construct is taken up and internalized by skin Langerhans cells via the receptor for this chemokine, which is called CCR6 (34) . The complex is then processed and presented in draining LNs to elicit efficient cellular and humoral responses (34) . Enhanced efficacy has been shown compared to antigen-only vaccines in various systems (20) (21) (22) . In a mouse melanoma model, our group has demonstrated that IM immunization with a DNA vaccine containing a fusion of MIP-3α with the tumor antigen gene gp100/Trp2 elicited greater numbers of tumor antigen-specific T cells and offered greater therapeutic benefit compared to the cognate vaccine lacking the MIP-3α fusion (20, 21) . Importantly, MIP-3α has also been shown to play a key role in driving DC recruitment to the nasal mucosa (35) . Indeed, we found that IM vaccination with the MIP-3α fusion construct conferred Wild-type Mtb H37Rv was grown in Middlebrook 7H9 broth (Difco, Sparks, MD) supplemented with 10% oleic acid-albumindextrose-catalase (OADC, Difco), 0.2% glycerol, and 0.05% Tween-80 at 37 o C in a roller bottle (3). The previously generated relMtb expression plasmid, pET15b[relMtb] (3, 19) , was used for was purified from the cell lysate using a Ni-NTA resin column. The purity was confirmed by SDS-PAGE gel and immunoblot analyses. The protein concentration was determined using a BCA protein assay with BSA as the standard (Thermo Fisher). Recombinant RelMtb has been shown previously to retain (p)ppGpp synthesis and hydrolysis activities and can serve as an antigen to measure RelMtb-specific T-cell responses ex vivo (3, 19) . The plasmid pSectag2B encoding the full-length relMtb gene was used as the relMtb DNA vaccine (19) . The relMtb gene was codon-optimized (Genscript) and fused to the mouse MIP-3α gene. The fusion product was cloned into pSectag2B, serving as the MIP-3α/relMtb DNA, fusion, vaccine or ( Figure 1A , detailed sequence in Supplementary Appendix). (19) . For IN immunizations, each plasmid was administered into both nostrils (50 μL in each nostril) and mice were monitored in the upright position until complete recovery and vaccine absorption were assured. The mice were sacrificed 6 weeks and 10 weeks after treatment initiation. The spleens and left lungs were harvested and processed into single-cell suspensions. The right lungs were homogenized using glass homogenizers. Serial tenfold dilutions of lung homogenates in PBS were plated on 7H11 selective agar (BD) at the indicated time points. Plates were incubated at 37 C and colony-forming units (CFU) were counted 4 weeks later (3, 19) . Male and female C57BL/6 mice (8-10-week-old, Charles River Laboratory) were randomized to receive the relMtb or the fusion DNA vaccine by the IM (20 or 200 μg) or IN (200 μg) route. The mice were sacrificed 6 weeks after the primary vaccination. Spleens, draining LNs, lungs and PBMCs were collected and processed into single-cell suspensions. All the single-cell suspensions from spleens, draining LNs, lungs and PBMCs were stimulated individually with purified recombinant RelMtb protein at 37C (3, 19) Pairwise comparisons of group mean values for log10 CFU (microbiology data) and flow cytometry data were made by using one-way analysis of variance followed by Tukey's multiple comparisons test. Prism 9.3 (GraphPad Software, Inc. San Diego, CA) was utilized for statistical analyses and figure creation. For correlation of two nominal predictor variables to a continuous outcome variable, two-way analysis of variance followed by Tukey's multiple comparisons test was utilized. To illustrate the aggragate cytokine data per group (Figure 4) , Fraction of total analysis was used and is displayed in stacked bars and pie charts. In Figure 4 , cytokine data were normalized (the total sum of all the experimental groups= 100%, total absolute number of alive cells=30,000). All error bars represent the estimation of the standard error of the mean, and all midlines represent the group mean. A significance level of α ≤ 0.05 was set for all experiments. All procedures were performed according to protocols approved by the Johns Hopkins University Institutional Animal Care and Use Committee. RelMtb-specific TNF-αproducing CD4+ T cells (G) and CD8+ T cells (H) in lungs; RelMtbspecific, IL-17αproducing CD4+ T cells in lungs (I) and spleens (J) (flow cytometryintracellular staining).. IM: Intramuscular (standard dose is shown), IN: Intranasal (high dose is shown). All statistically significant P values are available in Supplementary Table 2 . Y-axis scales are different among cytokines and between tissues in order to better demonstrate differences between groups where cytokine expression levels were lower. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination Timing of relapse in short-course chemotherapy trials for tuberculosis Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis Remembering the Host in Tuberculosis Drug Development Microbial persistence Inapparent infection: relation of latent and dormant infections to microbial persistence Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis Multiple antibiotic resistance in a bacterium with suppressed autolytic system The stringent response and Mycobacterium tuberculosis pathogenesis Targeting the Mycobacterium tuberculosis Stringent Response as a Strategy for Shortening Tuberculosis Treatment The stringent response of Mycobacterium tuberculosis is required for long-term survival The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa The Relative Importance of T Cell Subsets in Immunity and Immunopathology of Airborne Mycobacterium tuberculosis Infection in Mice Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis Initiation and regulation of T-cell responses in tuberculosis Th1 cytokines, true functional signatures for protective immunity against TB? Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis Immunobiology: The Immune System in Health and Disease Tuberculosis and HIV co-infection B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa Airway luminal T cells: a newcomer on the stage of TB vaccination strategies Single mucosal, but not parenteral, immunization with recombinant adenoviralbased vaccine provides potent protection from pulmonary tuberculosis Signaling Is Required for Restricted Homing of Parenteral Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway Cell-mediated immune responses in tuberculosis Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available IL-17α-spleen This work was supported by NIH grants: R21AI140860 and R01 AI148710 to RBM and PCK and T32 AI007291 to SK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Illustrations Figure 1B and, 3A were created with BioRender.com.